Genetesis
Developed CardioFlux, the first tool to non-invasively generate images of the heart’s electrical current distribution.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD108—162m (Dealroom.co estimates Oct 2022.)
Mason Ohio (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$260k | Seed | ||
$1.2m | Seed | ||
N/A | Grant | ||
$7.5m | Series A | ||
* | $9.2m | Series B | |
N/A | - | ||
* | $150k | Early VC | |
| $17.5m | Late VC | |
* | $17.5m | Series C | |
Total Funding | AUD82.4m |
Related Content
Recent News about Genetesis
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.